SAT-LB12 Once-Weekly Somapacitan vs Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Safety Results From Real 3, a Randomized Phase 2 Trial

Growth hormone (GH) replacement therapy currently requires daily injections. Somapacitan is a long-acting GH-derivative being developed for once-weekly (OW) use in children and adults with GH deficiency (GHD). A phase 2, multinational, randomized, open-label, controlled trial (ClinicalTrials.gov: NC...

Descripción completa

Detalles Bibliográficos
Autores principales: Savendahl, Lars S, Rasmussen, Michael Højby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209577/
http://dx.doi.org/10.1210/jendso/bvaa046.2309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209577/
http://dx.doi.org/10.1210/jendso/bvaa046.2309

Ejemplares similares